Showing results (191-200 of 339) with videos related to
Sort By:
Pageof 34
Peptides|March 11, 1991
Biotinylation of a bombesin/gastrin-releasing peptide analogue for use as a receptor probeP A Anton, J R Reeve, J E Rivier, et al.Journal of Cellular Physiology|October 31, 2000
Interferon-gamma sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosisJ O'Connell, M W Bennett, K Nally, et al.Aviation, Space, and Environmental Medicine|April 24, 2014
Helicopter crashes into water: warning time, final position, and other factors affecting survivalChristopher J Brooks, Conor V MacDonald, Susan P Baker, et al.Immunopharmacology|April 1, 1986
Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processesF Shanahan, A Niederlehner, R P MacDermott, et al.Immunopharmacology and Immunotoxicology|August 1, 1993
VIP modulates intracellular calcium oscillations in human lymphoblastsP A Anton, F Shanahan, X P Sun, et al.FEBS Letters|July 11, 1994
Substitution of conserved tyrosine residues in helix 4 (Y143) and 7 (Y293) affects the activity, but not IAPS-forskolin binding, of the glucose transporter GLUT4S Wandel, A Schürmann, W Becker, et al.Clinical and Diagnostic Laboratory Immunology|July 3, 1999
Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilegeJ O'Connell, M W Bennett, G C O'Sullivan, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|December 1, 1995
Mutation of two conserved arginine residues in the glucose transporter GLUT4 supresses transport activity, but not glucose-inhibitable binding of inhibitory ligandsS Wandel, A Schurmann, W Becker, et al.Calcified Tissue International|June 20, 2002
Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish populationF Wynne, F Drummond, K O'Sullivan, et al.QJM : Monthly Journal of the Association of Physicians|March 1, 1997
Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V LeidenL M Jackson, P J O'Gorman, J O'Connell, et al.Pageof 34